1. Allergen Immunotherapy and Atopic Dermatitis: the Good, the Bad, and the Unknown
- Author
-
Anna De Benedetto, Patrick Rizk, and Mario Rodenas
- Subjects
Pulmonary and Respiratory Medicine ,Allergen immunotherapy ,medicine.medical_specialty ,Allergy ,medicine.medical_treatment ,Immunology ,Dermatitis, Atopic ,03 medical and health sciences ,0302 clinical medicine ,Quality research ,Humans ,Immunology and Allergy ,Medicine ,media_common.cataloged_instance ,Practice Patterns, Physicians' ,European union ,030223 otorhinolaryngology ,media_common ,Asthma ,business.industry ,Immunotherapy ,Atopic dermatitis ,medicine.disease ,Dermatology ,Cost savings ,body regions ,030228 respiratory system ,Desensitization, Immunologic ,business - Abstract
In light of the recent advancements in atopic dermatitis treatment, this review aims to summarize the utility and efficacy of allergy immunotherapy in atopic dermatitis patients. We examine its mechanism, pathophysiology, cost-efficacy, and current guidelines for clinical practice. The literature supports the use of allergy immunotherapy in atopic conditions such as allergic rhinitis and asthma but insufficient evidence exists to suggest its efficacy in atopic dermatitis. The use of allergy immunotherapy has been shown to provide long-term cost savings in both the USA and the European Union in certain populations but differences in prescribing patterns and manufacturing make it difficult to study its impact on a larger, generalizable scale. Conflicting meta-analyses data and conclusions highlight the need for better, higher quality research to better understand allergy immunotherapy utility in atopic dermatitis.
- Published
- 2019
- Full Text
- View/download PDF